Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annu...(se for 90 days or more or acomplete or p...),Health

All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and 26 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to voreloxin therapy.

In March, based on the indications of clinical activity and the acceptable tolerability profile demonstrated in this Phase 2 clinical trial, Sunesis increased the dose of voreloxin in this trial to 60 mg/m(2) once every 28 days. Thirty-four patients have been enrolled at the 60 mg/m(2) dose level. To date, with an initial eight patients evaluable for efficacy response, one patient has achieved a partial response.

Voreloxin has been well-tolerated in the platinum-resistant ovarian cancer population. With 65 patients evaluable for safety at the 48 mg/m(2) dose and 20 patients evaluable for safety at the 60 mg/m(2) dose, low rates of febrile neutropenia (<10%) or other Grade 3-4 adverse events (fatigue (12%), vomiting (5%) and infections (5% )) have been observed. Based on voreloxin's safety profile, Sunesis recently announced that the protocol for the ongoing Phase 2 clinical trial was amended to increase the dose by 25 percent to 75 mg/m(2) given once every 28 days. Sunesis expects to enroll approximately 30 patients at this new dose level by the end of this year.

"Voreloxin has demonstrated promising clinical activity and tolerability among platinum-resistant ovarian cancer patients and we are focused on advancing this compound in this indication toward late-stage trials," said Daniel Swisher, Sunesis' Chief Executive Officer. "We are pleased by the rapid progress of enrollment of vorelo
'/>"/>